{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:27:36Z","timestamp":1787023656500,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Scientific Research Projects of Medical and Health Institutions of Longhua District, Shenzhen","award":["2022046"],"award-info":[{"award-number":["2022046"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10067-026-08047-5","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:20:20Z","timestamp":1774282820000},"page":"5093-5098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of telitacicept in a refractory systemic lupus erythematosus patient with lupus nephritis and subsequent pregnancy: a case-based review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9077-1593","authenticated-orcid":false,"given":"Jinhui","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"8047_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"key":"8047_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107466","volume":"94","author":"X Lu","year":"2021","unstructured":"Lu X, Wang Y, Zhang J, Pu D, Hu N, Luo J, An Q, He L (2021) Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int Immunopharmacol 94:107466","journal-title":"Int Immunopharmacol"},{"key":"8047_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137143","author":"M Morell","year":"2021","unstructured":"Morell M, P\u00e9rez-C\u00f3zar F, Mara\u00f1\u00f3n C (2021) Immune-related urine biomarkers for the diagnosis of lupus nephritis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22137143","journal-title":"Int J Mol Sci"},{"key":"8047_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103404","volume":"22","author":"M Xipell","year":"2023","unstructured":"Xipell M, Lled\u00f3 GM, Egan AC, Tamirou F, Del Castillo CS, Rovira J, G\u00f3mez-Puerta JA, Garc\u00eda-Herrera A, Cervera R, Kronbichler A et al (2023) From systemic lupus erythematosus to lupus nephritis: the evolving road to targeted therapies. Autoimmun Rev 22:103404","journal-title":"Autoimmun Rev"},{"key":"8047_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.autrev.2019.05.011","volume":"18","author":"A Mageau","year":"2019","unstructured":"Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L, Papo T, Sacre K (2019) The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev 18:733\u2013737","journal-title":"Autoimmun Rev"},{"key":"8047_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02846-z","volume":"23","author":"GT Hailu","year":"2022","unstructured":"Hailu GT, Hussen SU, Getachew S, Berha AB (2022) Management practice and treatment outcomes of adult patients with lupus nephritis at the Renal Clinic of St. Paul\u2019s Hospital Millennium Medical College, Addis Ababa, Ethiopia. BMC Nephrol 23:214","journal-title":"BMC Nephrol"},{"key":"8047_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1177\/0961203320930099","volume":"29","author":"G Ruiz-Irastorza","year":"2020","unstructured":"Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Khamashta M (2020) Seventy years after Hench\u2019s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus 29:1155\u20131167","journal-title":"Lupus"},{"key":"8047_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000590","author":"MF Ugarte-Gil","year":"2021","unstructured":"Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Re\u00e1tegui-Sokolova C, Elera-Fitzcarrald C, Aranow C, Arnaud L, Askanase AD et al (2021) Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2021-000590","journal-title":"Lupus Sci Med"},{"key":"8047_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.31138\/mjr.230124.uos","volume":"35","author":"D Martin-Iglesias","year":"2024","unstructured":"Martin-Iglesias D, Paredes-Ruiz D, Ruiz-Irastorza G (2024) Use of glucocorticoids in SLE: a clinical approach. Mediterr J Rheumatol 35:342\u2013353","journal-title":"Mediterr J Rheumatol"},{"key":"8047_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/1744666X.2025.2494654","volume":"21","author":"TC Mok","year":"2025","unstructured":"Mok TC, Mok CC (2025) Glucocorticoid in systemic lupus erythematosus: the art beyond science. Expert Rev Clin Immunol 21:543\u2013553","journal-title":"Expert Rev Clin Immunol"},{"key":"8047_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","volume":"82","author":"SA Bergstra","year":"2023","unstructured":"Bergstra SA, Sepriano A, Kerschbaumer A, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope JE, Takeuchi T et al (2023) Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82:81\u201394","journal-title":"Ann Rheum Dis"},{"key":"8047_CR12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1191\/0961203304lu2029ed","volume":"13","author":"A Raptopoulou","year":"2004","unstructured":"Raptopoulou A, Sidiropoulos P, Boumpas D (2004) Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 13:887\u2013890","journal-title":"Lupus"},{"key":"8047_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1191\/0961203303lu1028oa","volume":"13","author":"M Petri","year":"2004","unstructured":"Petri M (2004) Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13:366\u2013371","journal-title":"Lupus"},{"key":"8047_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103038","volume":"21","author":"S Giambalvo","year":"2022","unstructured":"Giambalvo S, Garaffoni C, Silvagni E, Furini F, Rizzo R, Govoni M, Bortoluzzi A (2022) Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 21:103038","journal-title":"Autoimmun Rev"},{"key":"8047_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, Hu J, Li Y, Li F, Huang C et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83:475\u2013487","journal-title":"Ann Rheum Dis"},{"key":"8047_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X, Li Z, Ma B, Niu L, Wang P, Pan HF, Li SD, Bao W et al (2023) Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2023-001074","journal-title":"Lupus Sci Med"},{"key":"8047_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671\u20131675","journal-title":"Drugs"},{"key":"8047_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C et al (2025) A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med 393:1475\u20131485","journal-title":"N Engl J Med"},{"key":"8047_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32:94\u2013100","journal-title":"Lupus"},{"key":"8047_CR20","unstructured":"Center for Drug Evaluation NMPA.Package insert for telitacicept for injection (CXSS1900040)[EB\/OL].(April 28, 2022)[October 31, 2025]. https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=b6e3c058f64eed2d1bf8f37ae5132e02."},{"key":"8047_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/1756-185X.14445","volume":"26","author":"SR Wei","year":"2023","unstructured":"Wei SR, Zhu ZZ, Xu J, Mo HY (2023) Favorable pregnancy outcomes in two patients with systemic lupus erythematosus treated with belimumab. Int J Rheum Dis 26:154\u2013156","journal-title":"Int J Rheum Dis"},{"key":"8047_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.semarthrit.2014.05.006","volume":"44","author":"A Danve","year":"2014","unstructured":"Danve A, Perry L, Deodhar A (2014) Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum 44:195\u2013197","journal-title":"Semin Arthritis Rheum"},{"key":"8047_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/ard-2022-222505","volume":"82","author":"M Petri","year":"2023","unstructured":"Petri M, Landy H, Clowse MEB, Gemzoe K, Khamashta M, Kurtinecz M, Levy RA, Liu A, Marino R, Meizlik P et al (2023) Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis 82:217\u2013225","journal-title":"Ann Rheum Dis"},{"key":"8047_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/bdr2.2091","volume":"115","author":"P Juliao","year":"2023","unstructured":"Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, Tilson H, Covington D, Moore T, Marino R et al (2023) Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. Birth Defects Res 115:188\u2013204","journal-title":"Birth Defects Res"},{"key":"8047_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrrheum.2012.133","volume":"8","author":"A Lateef","year":"2012","unstructured":"Lateef A, Petri M (2012) Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol 8:710\u2013718","journal-title":"Nat Rev Rheumatol"},{"key":"8047_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795\u2013810","journal-title":"Ann Rheum Dis"},{"key":"8047_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF et al (2017) EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis 76:476\u2013485","journal-title":"Ann Rheum Dis"},{"key":"8047_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","volume":"20","author":"J Lichtnekert","year":"2024","unstructured":"Lichtnekert J, Anders HJ (2024) Lupus nephritis-related chronic kidney disease. Nat Rev Rheumatol 20:699\u2013711","journal-title":"Nat Rev Rheumatol"},{"key":"8047_CR29","first-page":"1","volume":"65","author":"KM Curtis","year":"2016","unstructured":"Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK (2016) U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 65:1\u2013103","journal-title":"MMWR Recomm Rep"},{"key":"8047_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/art.37719","volume":"65","author":"CC Mok","year":"2013","unstructured":"Mok CC, Chan PT, To CH (2013) Anti-m\u00fcllerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum 65:206\u2013210","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08047-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:17:18Z","timestamp":1787023038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08047-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8047"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08047-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the ethics committee of The People's Hospital Longhua Shenzhen. The patient provided written informed consent for the case study to be published.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The patient who participated in the study provided written informed consent for the publication of any associated data and images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}